Resumo

NAVARRETE-TAPIA, Ulises et al. Effect of metformin on obesity associated metabolic phenotypes. Rev. Mex. Cardiol [online]. 2016, vol.27, n.1, pp.26-33. ISSN 0188-2198.

Background: It is known that there are different metabolic phenotypes associated with obesity, each of them imposing distinct cardiovascular risk. Metformin is a drug with wide and diverse applications in cardiometabolic disorders. Aims: To determine the effect of metformin on lipid profile, glucose metabolism and anthropometric variables of different phenotypes of obesity. Material and methods: We conducted a "before and after" clinical trial in order to evaluate the response to metformin treatment (850 mg/day for 24 weeks). Variables like body weight, body mass index (BMI), waist-hip index (WHI), blood pressure, glycemia, total cholesterol (TC) and its fractions, HDL, LDL as well as triglycerides and TC/HDL-c and TG/HDL-c lipoprotein indexes were analyzed at baseline and at the end of the trial. Results: HDL-c and TC/HDL-c ratios showed a considerable improvement after treatment. A reduction in LDL fraction was observed. Triglyceride levels had no significant changes. An average weight reduction of 0.48 Kg was obtained alongside with an improvement of the BMI. Both systolic and diastolic blood pressures did not show meaningful changes. Conclusions: Sustained administration of metformin had a beneficial effect on lipid profile, weight reduction and cardiovascular risk predictors.

Palavras-chave : Metformin; metabolic phenotypes; obesity.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )